About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 692071, 13 pages
http://dx.doi.org/10.1155/2013/692071
Review Article

Role of the Plasma Membrane Transporter of Organic Cations OCT1 and Its Genetic Variants in Modern Liver Pharmacology

1Laboratory of Experimental Hepatology and Drug Targeting (HEVEFARM), Biomedical Research Institute of Salamanca (IBSAL), University of Salamanca, Campus Miguel de Unamuno, E.D. S-09, 37007 Salamanca, Spain
2Department of Physiology and Pharmacology, University of Salamanca, Campus Miguel de Unamuno, E.D. S-09, 37007 Salamanca, Spain
3National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Instituto de Salud Carlos III, Sinesio Delgado 4, 28029 Madrid, Spain

Received 30 April 2013; Accepted 4 July 2013

Academic Editor: Hongqun Liu

Copyright © 2013 Elisa Lozano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Bruix, J. L. Raoul, M. Sherman et al., “Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial,” Journal of Hepatology, vol. 57, pp. 821–829, 2012.
  2. P. Martinez-Becerra, J. Vaquero, M. R. Romero et al., “No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors,” Molecular Pharmacology, vol. 9, pp. 1693–1704, 2012.
  3. E. Herraez, E. Lozano, R. I. Macias et al., “The expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib,” Hepatology, 2013. View at Publisher · View at Google Scholar
  4. T. Minematsu and K. M. Giacomini, “Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins,” Molecular Cancer Therapeutics, vol. 10, no. 3, pp. 531–539, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Shikata, R. Yamamoto, H. Takane et al., “Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin,” Journal of Human Genetics, vol. 52, no. 2, pp. 117–122, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Zhang, K. S. Lovejoy, J. E. Shima et al., “Organic cation transporters are determinants of oxaliplatin cytotoxicity,” Cancer Research, vol. 66, no. 17, pp. 8847–8857, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Koepsell, K. Lips, and C. Volk, “Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications,” Pharmaceutical Research, vol. 24, no. 7, pp. 1227–1251, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. D. K. Meijer, W. E. Mol, M. Müller, and G. Kurz, “Carrier-mediated transport in the hepatic distribution and elimination of drugs, with special reference to the category of organic cations,” Journal of Pharmacokinetics and Biopharmaceutics, vol. 18, no. 1, pp. 35–70, 1990. View at Publisher · View at Google Scholar · View at Scopus
  9. B. M. Schmitt and H. Koepsell, “Alkali cation binding and permeation in the rat organic cation transporter rOCT2,” Journal of Biological Chemistry, vol. 280, no. 26, pp. 24481–24490, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. J. E. van Montfoort, M. Müller, G. M. M. Groothuis, D. K. F. Meijer, H. Koepsell, and P. J. Meier, “Comparison of “type I” and “type II” organic cation transport by organic cation transporters and organic anion-transporting polypeptides,” Journal of Pharmacology and Experimental Therapeutics, vol. 298, no. 1, pp. 110–115, 2001. View at Scopus
  11. H. Koepsell and H. Endou, “The SLC22 drug transporter family,” Pflugers Archiv, vol. 447, no. 5, pp. 666–676, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Koepsell, “The SLC22 family with transporters of organic cations, anions and zwitterions,” Molecular Aspects of Medicine, vol. 34, pp. 413–435, 2013.
  13. D. Gründemann, V. Gorboulev, S. Gambaryan, M. Veyhl, and H. Koepsell, “Drug excretion mediated by a new prototype of polyspecific transporter,” Nature, vol. 372, no. 6506, pp. 549–552, 1994. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Zhang, M. J. Dresser, A. T. Gray, S. C. Yost, S. Terashita, and K. M. Giacomini, “Cloning and functional expression of a human liver organic cation transporter,” Molecular Pharmacology, vol. 51, no. 6, pp. 913–921, 1997. View at Scopus
  15. R. M. Green, K. Lo, C. Sterritt, and D. R. Beier, “Cloning and functional expression of a mouse liver organic cation transporter,” Hepatology, vol. 29, no. 5, pp. 1556–1562, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. M. R. Koehler, B. Wissinger, V. Gorboulev, H. Koepsell, and M. Schmid, “The two human organic cation transporter genes SLC22A1 and SLC22A2 are located on chromosome 6q26,” Cytogenetics and Cell Genetics, vol. 79, no. 3-4, pp. 198–200, 1997. View at Scopus
  17. D. Gründemann and E. Schömig, “Gene structures of the human non-neuronal monoamine transporters EMT and OCT2,” Human Genetics, vol. 106, no. 6, pp. 627–635, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Hayer, H. Bönisch, and M. Brüss, “Molecular cloning, functional characterization and genomic organization of four alternatively spliced isoforms of the human organic cation transporter 1 (hOCT1/SLC22A1),” Annals of Human Genetics, vol. 63, no. 6, pp. 473–482, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. S. H. Wright, “Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics,” Toxicology and Applied Pharmacology, vol. 204, no. 3, pp. 309–319, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Burckhardt and N. A. Wolff, “Structure of renal organic anion and cation transporters,” American Journal of Physiology, vol. 278, no. 6, pp. F853–F866, 2000. View at Scopus
  21. S. A. Eraly, K. T. Bush, R. V. Sampogna, V. Bhatnagar, and S. K. Nigam, “The molecular pharmacology of organic anion transporters: from DNA to FDA?” Molecular Pharmacology, vol. 65, no. 3, pp. 479–487, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Popp, V. Gorboulev, T. D. Müller, D. Gorbunov, N. Shatskaya, and H. Koepsell, “Amino acids critical for substrate affinity of rat organic cation transporter 1 line the substrate binding region in a model derived from the tertiary structure of lactose permease,” Molecular Pharmacology, vol. 67, no. 5, pp. 1600–1611, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Koepsell, “Substrate recognition and translocation by polyspecific organic cation transporters,” Biological Chemistry, vol. 392, no. 1-2, pp. 95–101, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. J. J. G. Marin, O. Briz, M. J. Monte, A. G. Blazquez, and R. I. R. Macias, “Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs,” Current Cancer Drug Targets, vol. 12, no. 4, pp. 402–438, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. M. K. Leabman, C. C. Huang, J. DeYoung et al., “Natural variation in human membrane transporter genes reveals evolutionary and functional constraints,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 10, pp. 5896–5901, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Kerb, U. Brinkmann, N. Chatskaia et al., “Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences,” Pharmacogenetics, vol. 12, no. 8, pp. 591–595, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Saito, A. Iida, A. Sekine et al., “Catalog of 238 variations among six human genes encoding solute carriers (hSLCs) in the Japanese population,” Journal of Human Genetics, vol. 47, no. 11, pp. 576–584, 2002. View at Scopus
  28. M. Itoda, Y. Saito, K. Maekawa et al., “Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1),” Drug Metabolism and Pharmacokinetics, vol. 19, no. 4, pp. 308–312, 2004. View at Scopus
  29. L. Tarasova, I. Kalnina, K. Geldnere et al., “Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients,” Pharmacogenetics and Genomics, vol. 22, pp. 659–666, 2012.
  30. Y. Shu, M. K. Leabman, B. Feng et al., “Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 10, pp. 5902–5907, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. H. K. Dong, L. Sriharsha, W. Xu et al., “Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia,” Clinical Cancer Research, vol. 15, no. 14, pp. 4750–4758, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Takeuchi, H. Motohashi, M. Okuda, and K. Inui, “Decreased function of genetic variants, Pro283Leu and Arg287Gly, in human organic cation transporter hOCT1,” Drug Metabolism and Pharmacokinetics, vol. 18, pp. 409–412, 2003.
  33. T. Sakata, N. Anzai, H. J. Shin et al., “Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions,” Biochemical and Biophysical Research Communications, vol. 313, no. 3, pp. 789–793, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. A. T. Nies, H. Koepsell, S. Winter et al., “Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver,” Hepatology, vol. 50, no. 4, pp. 1227–1240, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Chen, M. Takizawa, E. Chen et al., “Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function,” Journal of Pharmacology and Experimental Therapeutics, vol. 335, no. 1, pp. 42–50, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Shu, S. A. Sheardown, C. Brown et al., “Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action,” Journal of Clinical Investigation, vol. 117, no. 5, pp. 1422–1431, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. J. W. Langston, P. Ballard, J. W. Tetrud, and I. Irwin, “Chronic parkinsonism in humans due to a product of meperidine-analog synthesis,” Science, vol. 219, no. 4587, pp. 979–980, 1983. View at Scopus
  38. M. C. Yang, A. J. McLean, and D. G. Le Couteur, “Cell membrane transport of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)in the liver and systemic bioavailability,” Biochemical and Biophysical Research Communications, vol. 289, no. 1, pp. 130–136, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. M. L. Becker, L. E. Visser, R. H. N. van Schaik, A. Hofman, A. G. Uitterlinden, and B. H. C. Stricker, “Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus,” Pharmacogenomics Journal, vol. 9, no. 4, pp. 242–247, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. M. L. Becker, L. E. Visser, R. H. N. van Schaik, A. Hofman, A. G. Uitterlinden, and B. H. C. Stricker, “OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users,” Neurogenetics, vol. 12, no. 1, pp. 79–82, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. M.-K. Choi and I.-S. Song, “Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake,” Biopharmaceutics and Drug Disposition, vol. 33, no. 3, pp. 170–178, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Li, Y. Chen, S. Zhang, S. S. More, X. Huang, and K. M. Giacomini, “Role of organic cation transporter 1, OCT1 in the pharmacokinetics and toxicity of cis-diammine(pyridine)chloroplatinum(II) and oxaliplatin in mice,” Pharmaceutical Research, vol. 28, no. 3, pp. 610–625, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. M. V. Tzvetkov, A. R. Saadatmand, K. Bokelmann, I. Meineke, R. Kaiser, and J. Brockmöller, “Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT 3 antagonists tropisetron and ondansetron,” Pharmacogenomics Journal, vol. 12, no. 1, pp. 22–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. J. W. Jonker and A. H. Schinkel, “Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3).,” Journal of Pharmacology and Experimental Therapeutics, vol. 308, no. 1, pp. 2–9, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. D.-S. Wang, J. W. Jonker, Y. Kato, H. Kusuhara, A. H. Schinkel, and Y. Sugiyama, “Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin,” Journal of Pharmacology and Experimental Therapeutics, vol. 302, no. 2, pp. 510–515, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. L. C. Crossman, B. J. Druker, M. W. N. Deininger, M. Pirmohamed, L. Wang, and R. E. Clark, “hOCT 1 and resistance to imatinib,” Blood, vol. 106, no. 3, pp. 1133–1134, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Wang, A. Giannoudis, S. Lane, P. Williamson, M. Pirmohamed, and R. E. Clark, “Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia,” Clinical Pharmacology and Therapeutics, vol. 83, no. 2, pp. 258–264, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Nardinelli, S. S. Sanabani, A. Didone et al., “Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia,” Acta Haematologica, vol. 127, no. 4, pp. 228–234, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Giannoudis, L. Wang, A. L. Jorgensen et al., “The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia,” Blood, vol. 121, pp. 628–637, 2013.
  50. V. Gorboulev, J. C. Ulzheimer, A. Akhoundova et al., “Cloning and characterization of two human polyspecific organic cation transporters,” DNA and Cell Biology, vol. 16, no. 7, pp. 871–881, 1997.
  51. F. Meyer-Wentrup, U. Karbach, V. Gorboulev, P. Arndt, and H. Koepsell, “Membrane localization of the electrogenic cation transporter rOCT1 in rat liver,” Biochemical and Biophysical Research Communications, vol. 248, no. 3, pp. 673–678, 1998. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Lautem, M. Heise, A. Grasel et al., “Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma,” International Journal of Oncology, vol. 42, no. 4, pp. 1297–1304, 2013. View at Publisher · View at Google Scholar
  53. S. Verhaagh, N. Schweifer, D. P. Barlow, and R. Zwart, “Cloning of the mouse and human solute carrier 22a3 (Slc22a3/SLC22A3) identifies a conserved cluster of three organic cation transporters on mouse chromosome 17 and human 6q26-q27,” Genomics, vol. 55, no. 2, pp. 209–218, 1999. View at Publisher · View at Google Scholar · View at Scopus
  54. A. E. Busch, U. Karbach, D. Miska et al., “Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine,” Molecular Pharmacology, vol. 54, no. 2, pp. 342–352, 1998. View at Scopus
  55. M. J. Dresser, A. T. Gray, and K. M. Giacomini, “Kinetic and selectivity differences between rodent, rabbit, and human organic cation transporters (OCT1),” Journal of Pharmacology and Experimental Therapeutics, vol. 292, no. 3, pp. 1146–1152, 2000. View at Scopus
  56. T. Mehrens, S. Lelleck, I. Çetinkaya et al., “The affinity of the organic cation transporter rOCT1 is increased by protein kinase C-dependent phosphorylation,” Journal of the American Society of Nephrology, vol. 11, no. 7, pp. 1216–1224, 2000. View at Scopus
  57. E. Schlatter, V. Mönnich, I. Çetinkaya et al., “The organic cation transporters rOCT1 and hOCT2 are inhibited by cGMP,” Journal of Membrane Biology, vol. 189, no. 3, pp. 237–244, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. A. T. Nies, E. Herrmann, M. Brom, and D. Keppler, “Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1),” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 376, no. 6, pp. 449–461, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. K. K. Moon and C.-K. Shim, “The transport of organic cations in the small intestine: current knowledge and emerging concepts,” Archives of Pharmacal Research, vol. 29, no. 7, pp. 605–616, 2006. View at Scopus
  60. T. Yasujima, K. Ohta, K. Inoue, and H. Yuasa, “Characterization of human OCT1-mediated transport of DAPI as a fluorescent probe substrate,” Journal of Pharmaceutical Sciences, vol. 100, no. 9, pp. 4006–4012, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. G. Ahlin, J. Karlsson, J. M. Pedersen et al., “Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1,” Journal of Medicinal Chemistry, vol. 51, no. 19, pp. 5932–5942, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. D. Bednarczyk, E. A. Mash, B. R. Aavula, and S. H. Wright, “NBD-TMA: a novel fluorescent substrate of the peritubular organic cation transporter of renal proximal tubules,” Pflugers Archiv, vol. 440, no. 1, pp. 184–192, 2000. View at Publisher · View at Google Scholar · View at Scopus
  63. W.-K. Lee, N. A. Wolff, and F. Thévenod, “Organic cation transporters: physiology, toxicology and special focus on ethidium as a novel substrate,” Current Drug Metabolism, vol. 10, no. 6, pp. 617–631, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Chen, S. Zhang, M. Sorani, and K. M. Giacomini, “Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family,” Journal of Pharmacology and Experimental Therapeutics, vol. 322, no. 2, pp. 695–700, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. N. Kimura, S. Masuda, T. Katsura, and K.-I. Inui, “Transport of guanidine compounds by human organic cation transporters, hOCT1 and hOCT2,” Biochemical Pharmacology, vol. 77, no. 8, pp. 1429–1436, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. K. Tachampa, M. Takeda, S. Khamdang et al., “Interactions of organic anion transporters and organic cation transporters with mycotoxins,” Journal of Pharmacological Sciences, vol. 106, no. 3, pp. 435–443, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. H. Koepsell, “Polyspecific organic cation transporters: their functions and interactions with drugs,” Trends in Pharmacological Sciences, vol. 25, no. 7, pp. 375–381, 2004. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Sala-Rabanal, D. C. Li, G. R. Dake et al., “Polyamine transport by the polyspecific organic cation transporters OCT1, OCT2, and OCT3,” Molecular Pharmaceutics, vol. 10, pp. 1450–1458, 2013.
  69. D. Gründemann, C. Hahne, R. Berkels, and E. Schömig, “Agmatine is efficiently transported by non-neuronal monoamine transporters extraneuronal monoamine transporter (EMT) and organic cation transporter 2 (OCT2),” Journal of Pharmacology and Experimental Therapeutics, vol. 304, no. 2, pp. 810–817, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. H. Kimura, M. Takeda, S. Narikawa, A. Enomoto, K. Ichida, and H. Endou, “Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins,” Journal of Pharmacology and Experimental Therapeutics, vol. 301, no. 1, pp. 293–298, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. C. Lemos, A. Faria, M. Meireles, F. Martel, R. Monteiro, and C. Calhau, “Thiamine is a substrate of organic cation transporters in Caco-2 cells,” European Journal of Pharmacology, vol. 682, no. 1–3, pp. 37–42, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Masuda, T. Terada, A. Yonezawa et al., “Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2,” Journal of the American Society of Nephrology, vol. 17, no. 8, pp. 2127–2135, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. P. de Deyn, B. Marescau, W. Lornoy, I. Becaus, and A. Lowenthal, “Guanidino compounds in uraemic dialysed patients,” Clinica Chimica Acta, vol. 157, no. 2, pp. 143–150, 1986. View at Scopus
  74. B. K. Kishore, Z. Kallay, and P. M. Tulkens, “Clinico-biochemical aspects of guanidine compounds in uraemic toxicity,” International Urology and Nephrology, vol. 21, no. 2, pp. 223–232, 1989. View at Scopus
  75. S. Harlfinger, C. Fork, A. Lazar, E. Schömig, and D. Gründemann, “Are organic cation transporters capable of transporting prostaglandins?” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 372, no. 2, pp. 125–130, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Hayer-Zillgen, M. Brüss, and H. Bönisch, “Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3,” British Journal of Pharmacology, vol. 136, no. 6, pp. 829–836, 2002. View at Publisher · View at Google Scholar · View at Scopus
  77. E. Schaeffeler, C. Hellerbrand, A. T. Nies et al., “DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma,” Genome Medicine, vol. 3, no. 12, article 82, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. R. A. Casero Jr. and A. E. Pegg, “Polyamine catabolism and disease,” Biochemical Journal, vol. 421, no. 3, pp. 323–338, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. L. Zhang, M. E. Schaner, and K. M. Giacomini, “Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa),” Journal of Pharmacology and Experimental Therapeutics, vol. 286, no. 1, pp. 354–361, 1998. View at Scopus
  80. D. Gründemann, B. Schechinger, G. A. Rappold, and E. Schömig, “Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter,” Nature Neuroscience, vol. 1, no. 5, pp. 349–351, 1998. View at Scopus
  81. J. Müller, K. S. Lips, L. Metzner, R. H. H. Neubert, H. Koepsell, and M. Brandsch, “Drug specificity and intestinal membrane localization of human organic cation transporters (OCT),” Biochemical Pharmacology, vol. 70, no. 12, pp. 1851–1860, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. G. Ciarimboli and E. Schlatter, “Regulation of organic cation transport,” Pflugers Archiv, vol. 449, no. 5, pp. 423–441, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. G. Ciarimboli, K. Struwe, P. Arndt et al., “Regulation of the human organic cation transporter hOCT1,” Journal of Cellular Physiology, vol. 201, no. 3, pp. 420–428, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. F. Martel, E. Keating, C. Calhau, D. Gründemann, E. Schömig, and I. Azevedo, “Regulation of human extraneuronal monoamine transporter (hEMT) expressed in HEK293 cells by intracellular second messenger systems,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 364, no. 6, pp. 487–495, 2001. View at Publisher · View at Google Scholar · View at Scopus
  85. G. Ciarimboli, H. Koepsell, M. Iordanova et al., “Individual PKC-phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation,” Journal of the American Society of Nephrology, vol. 16, no. 6, pp. 1562–1570, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Saborowski, G. A. Kullak-Ublick, and J. J. Eloranta, “The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4α,” Journal of Pharmacology and Experimental Therapeutics, vol. 317, no. 2, pp. 778–785, 2006. View at Publisher · View at Google Scholar · View at Scopus
  87. M. Heise, A. Lautem, J. Knapstein et al., “Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance,” BMC Cancer, vol. 12, article 109, 2012. View at Publisher · View at Google Scholar · View at Scopus
  88. M. V. Tzvetkov, A. R. Saadatmand, J. Lötsch, I. Tegeder, J. C. Stingl, and J. Brockmöller, “Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol,” Clinical Pharmacology and Therapeutics, vol. 90, no. 1, pp. 143–150, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. D. Dickens, A. Owen, A. Alfirevic et al., “Lamotrigine is a substrate for OCT1 in brain endothelial cells,” Biochemical Pharmacology, vol. 83, no. 6, pp. 805–814, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. K. Watanabe, T. Sawano, T. Endo, M. Sakata, and J. Sato, “Studies on intestinal absorption of sulpiride (2): transepithelial transport of sulpiride across the human intestinal cell line Caco-2,” Biological and Pharmaceutical Bulletin, vol. 25, no. 10, pp. 1345–1350, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. K.-I. Umehara, T. Iwatsubo, K. Noguchi, and H. Kamimura, “Functional involvement of organic cation transporter1 (OCT1/Oct1) in the hepatic uptake of organic cations in humans and rats,” Xenobiotica, vol. 37, no. 8, pp. 818–831, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. G. Ciarimboli, R. Schroter, U. Neugebauer et al., “Kidney transplantation down-regulates expression of organic cation transporters, which translocate beta-blockers and fluoroquinolones,” Molecular Pharmacology, vol. 10, pp. 2370–2380, 2013.
  93. A. Mulgaonkar, J. Venitz, D. Grundemann, and D. H. Sweet, “Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials,” Antimicrobial Agents and Chemotherapy, vol. 57, no. 6, pp. 2705–2711, 2013.
  94. S. Gupta, G. Wulf, M. Henjakovic, H. Koepsell, G. Burckhardt, and Y. Hagos, “Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel,” Journal of Pharmacology and Experimental Therapeutics, vol. 341, no. 1, pp. 16–23, 2012. View at Publisher · View at Google Scholar · View at Scopus
  95. O. Briz, M. A. Serrano, N. Rebollo et al., “Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells,” Molecular Pharmacology, vol. 61, no. 4, pp. 853–860, 2002. View at Publisher · View at Google Scholar · View at Scopus
  96. M. Bayer, Z. Kuçi, E. Schömig et al., “Uptake of mIBG and catecholamines in noradrenaline- and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma- and pheochromocytoma cells,” Nuclear Medicine and Biology, vol. 36, no. 3, pp. 287–294, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. T. Minematsu, M. Iwai, K. Sugimoto et al., “Carrier-mediated uptake of 1 -(2-methoxyethyl)-2-methyl-4,9-dioxo-3- (pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium Bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells,” Drug Metabolism and Disposition, vol. 37, no. 3, pp. 619–628, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. J. Thomas, L. Wang, R. E. Clark, and M. Pirmohamed, “Active transport of imatinib into and out of cells: implications for drug resistance,” Blood, vol. 104, no. 12, pp. 3739–3745, 2004. View at Publisher · View at Google Scholar · View at Scopus
  99. C. Schmidt-Lauber, S. Harrach, T. Pap et al., “Transport mechanisms and their pathology-induced regulation govern tyrosine kinase inhibitor delivery in rheumatoid arthritis,” PLoS One, vol. 7, Article ID e52247, 2012.
  100. X. Ming, W. Ju, H. Wu, R. R. Tidwell, J. E. Hall, and D. R. Thakker, “Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters,” Drug Metabolism and Disposition, vol. 37, no. 2, pp. 424–430, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. N. Jung, C. Lehmann, A. Rubbert et al., “Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection,” Drug Metabolism and Disposition, vol. 36, no. 8, pp. 1616–1623, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. M. Takeda, S. Khamdang, S. Narikawa et al., “Human organic anion transporters and human organic cation transporters mediate renal antiviral transport,” Journal of Pharmacology and Experimental Therapeutics, vol. 300, no. 3, pp. 918–924, 2002. View at Publisher · View at Google Scholar · View at Scopus
  103. M. Aouida, A. Leduc, H. Wang, and D. Ramotar, “Characterization of a transport and detoxification pathway for the antitumour drug bleomycin in Saccharomyces cerevisiae,” Biochemical Journal, vol. 384, no. 1, pp. 47–58, 2004. View at Publisher · View at Google Scholar · View at Scopus
  104. H. Koepsell, “Organic cation transporters in intestine, kidney, liver, and brain,” Annual Review of Physiology, vol. 60, pp. 243–266, 1998. View at Publisher · View at Google Scholar · View at Scopus
  105. S. S. More, S. Li, S. W. Yee et al., “Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue,” Molecular Cancer Therapeutics, vol. 9, no. 4, pp. 1058–1069, 2010. View at Publisher · View at Google Scholar · View at Scopus
  106. J. J. Marin, R. I. Macias, J. J. Criado, A. Bueno, M. J. Monte, and M. A. Serrano, “DNA interaction and cytostatic activity of the new liver organotropic complex of cisplatin with glycocholic acid: Bamet-R2,” International Journal of Cancer, vol. 78, pp. 346–352, 1998.
  107. M. F. Dominguez, R. I. R. Macias, I. Izco-Basurko et al., “Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors,” Journal of Pharmacology and Experimental Therapeutics, vol. 297, no. 3, pp. 1106–1112, 2001. View at Scopus
  108. J. T. Hartmann, M. Haap, H.-G. Kopp, and H.-P. Lipp, “Tyrosine kinase inhibitors—a review on pharmacology, metabolism and side effects,” Current Drug Metabolism, vol. 10, no. 5, pp. 470–481, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. P. A. Philip, M. R. Mahoney, C. Allmer et al., “Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer,” Journal of Clinical Oncology, vol. 23, no. 27, pp. 6657–6663, 2005. View at Publisher · View at Google Scholar · View at Scopus
  110. M. Matsuo, H. Sakurai, and I. Saiki, “ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model,” Molecular Cancer Therapeutics, vol. 2, no. 6, pp. 557–561, 2003. View at Scopus
  111. S. M. Wilhelm, C. Carter, L. Tang et al., “BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis,” Cancer Research, vol. 64, no. 19, pp. 7099–7109, 2004. View at Publisher · View at Google Scholar · View at Scopus
  112. B. Swift, N. Nebot, J. K. Lee et al., “Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites,” Drug Metabolism and Disposition, vol. 41, no. 6, pp. 1179–1186, 2013.
  113. J. Kindla, M. F. Fromm, and J. König, “In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions,” Expert Opinion on Drug Metabolism and Toxicology, vol. 5, no. 5, pp. 489–500, 2009. View at Publisher · View at Google Scholar · View at Scopus